EMA committee recommends Yuviwel (navepegritide) for children with achondroplasia

Ta vnos je prikazan v angleščini, dokler njegov prevod ne bo posodobljen.

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended authorising Yuviwel (navepegritide), a prodrug containing C-type natriuretic peptide, for children aged 2 years and older with genetically confirmed achondroplasia whose epiphyses (bone growth plates) are not closed. In a 52-week randomised, double-blind, placebo-controlled trial, it improved annualised growth velocity by 1.49 cm compared with placebo. The most common side effects were injection site reactions and hypertrichosis (abnormal hair growth). A CHMP opinion is followed by a European Commission decision.

Viri

  1. 01Yuviwel: opinion on marketing authorisation(odpre vir v novem zavihku) European Medicines Agency
  2. 02Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026(odpre vir v novem zavihku) European Medicines Agency